Products
c-Met antibody
- Product Name
- c-Met antibody
- Catalogue No.
- FNab01786
- Size
- 100μg
- Form
- liquid
- Purification
- Immunogen affinity purified
- Purity
- ≥95% as determined by SDS-PAGE
- Clonality
- polyclonal
- Isotype
- IgG
- Storage
- PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
- Immunogen
- met proto-oncogene(hepatocyte growth factor receptor)
- Alternative Names
- AUTS9 antibody, c-Met antibody, HGF receptor antibody, HGF/SF receptor antibody, HGFR antibody, MET antibody, Proto oncogene c Met antibody, RCCP2 antibody, Scatter factor receptor antibody, SF receptor antibody, Tyrosine protein kinase Met antibody
- UniProt ID
- P08581
- Observed MW
- 150 kDa
Application
- Tested Applications
- ELISA, WB, IHC
- Recommended dilution
- WB: 1:500-1:1000; IHC: 1:50-1:200
Validated Images
HeLa cells were subjected to SDS PAGE followed by western blot with FNab01786(MET antibody) at dilution of 1:500
Immunohistochemistry of paraffin-embedded human breast cancer tissue slide using FNab01786(MET Antibody) at dilution of 1:50
- Background
- c-Met(also named as MET or HGFR) is a receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. c-Met regulates many physiological processes including proliferation, scattering, morphogenesis and survival. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Overexpression and/or mutation of c-Met has been reported in various human malignancies, including lung cancer, breast cancer, head and neck cancer, gastric cancer, colorectal cancer, bladder cancer, uterine cervix carcinoma, and esophageal carcinoma, c-Met could serve as an important therapeutic target(PMID: 26036285). This antibody recognizes the N-term of c-Met.
